What Is a 10-Panel Drug Test? Drugs Detected, Cost & Accuracy?
Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated August 2026
Quick answer: A 10-panel drug test screens for the following drug classes — see the full list below with cutoffs.
Complete drug list
Standard configuration with typical urine immunoassay cutoffs:
| Drug class | Typical urine cutoff |
|---|---|
| THC | 50 / 15 |
| Cocaine | 150 / 100 |
| Opiates incl. heroin | 2000 / 2000 |
| Amphetamines | 500 / 250 |
| PCP | 25 / 25 |
| Barbiturates | ~250–300 |
| Benzodiazepines | ~300 / 200 |
| Methadone | ~300 / EDDP |
| MDMA | 500 / 250 |
| Propoxyphene/propoxyphene (legacy) | ~300 |
Who uses this panel
The default 'general workforce' panel for many non-DOT employers — everything DOT tests plus depressants and ecstasy.
What it does NOT catch
Blind spots: Oxycodone/hydrocodone slots vary; buprenorphine, fentanyl, kratom, shrooms, LSD absent. Absence from the strip means no testing occurs — specialty panels extend coverage when programs need it.
Cost & logistics
Cash-pay pricing for a 10-panel typically runs $30–$100 depending on lab network and turnaround. Results release in 1–2 business days for negatives; positives add confirmation and MRO review time. Home versions of most cup sizes sell for $15–$45 at pharmacies.
Certified labs nationwide · Results in 1–2 days
Need a test? Order online, test same-day →People also ask
How accurate are drug tests?
Lab-based immunoassay screens agree with confirmation testing ~97% of the time; confirmed GC–MS results are considered definitive. Home kits trade legal defensibility for convenience.
Do prescriptions count against me?
No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.
Sources & further reading
- SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
- DOT — 49 CFR Part 40 procedures for transportation workplace testing
- Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
- FDA — drug-of-abuse test device labeling (detection window conventions)